ClinicalTrials.gg

Program

PRMT5 Inhibitor SH3765

Also written as “SH3765+Fulvestrant” and “SH3765 tablet”.

Its studies are mostly in Breast Neoplasms, led by Nanjing Sanhome Pharmaceutical.

Furthest: phase 1, since Aug 18, 20212 company-led studies, 1 open or runningNext primary completion: Jun 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nanjing Sanhome Pharmaceutical21 open or runningphase 1since Aug 18, 2021Aug 18, 2021Jun 30, 2027phase 1 · NCT07557004

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 18, 2021First study: phase 1 study in Advanced Malignant TumorFirst studyNCT05015309 · 40 enrolled · China
  2. Apr 15, 2026Phase 1 study in HR+ / HER2- Advanced Breast CancerNCT07557004 · 30 enrolled · China

Ahead

  1. Jun 30, 2027Primary completion: phase 1 study in HR+ / HER2- Advanced Breast CancerNCT07557004

TargetBeta

PRMT5 →read by rule
“An orally bioavailable inhibitor of protein arginine methyltransferase 5 (PRMT5), ”NCIt, by rule

Other programs on PRMT5

ProgramCompanyFurthest phaseStudies
navlimetostatBristol-Myers Squibbphase 310
PRMT5 Inhibitor AZD3470AstraZenecaphase 22
JBI-778rulejubilant-therapeutics-india-limitedphase 22
PRMT5 Inhibitor TNG456ruletango-therapeutics-incphase 21
PRMT5 Inhibitor BAY 3713372ruleBayerphase 21
onametostatruleJohnson & Johnsonphase 12
PRMT5 Inhibitor BGB-58067ruleBeOne Medicinesphase 12
PRMT5 Inhibitor IDE892ruleideaya-biosciencesphase 11
PEP08rulepharmaenginephase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07557004HR+ / HER2- Advanced Breast Cancer · China1Active, not recruitingJun 30, 202730
NCT05015309Advanced Malignant Tumor · China1UNKNOWNMar 202340

How it is read

Names in the registry

  • “SH3765+Fulvestrant”, 1 entry
  • “SH3765 tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.